P/E ratio for Evoke Pharma (EVOK)
P/E ratio as of March 2025 (TTM): -1.22
According to Evoke Pharma 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.22034. At the end of 2022 the company had a P/E ratio of -12.2.
P/E ratio history for Evoke Pharma from 2013 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -12.2 | -51.55% |
| 2021 | -25.1 | -57.77% |
| 2020 | -59.5 | 1.07% |
| 2019 | -58.9 | -8.94% |
| 2018 | -64.7 | 100.38% |
| 2017 | -32.3 | 69.15% |
| 2016 | -19.1 | -8.9% |
| 2015 | -21.0 | -35.19% |
| 2014 | -32.3 | -52.08% |
| 2013 | -67.5 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 | -0.2479 | -79.69% | 🇺🇸 USA |
 | -143 | 11,611.08% | 🇺🇸 USA |
 | 13.5 | -1,207.03% | 🇺🇸 USA |
 | -20.3 | 1,566.20% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.